Prospective Biomarkers of SARS-CoV-2 Vaccine Seroconversion in Patients with Haematological Malignancies
These results suggest that HM patients have impaired T-cell immunity, and non-responders may be identified by low levels of serum CXCL13 and CRTAM. This allows for the identification of at-risk patients who would benefit from alternative COVID-19 prophylaxis strategies.
Authors
- Michelle M. Spanevello (ORCID: https://orcid.org/0000-0003-1498-7822)
- Pauline Crooks
- Kirk Morris
- Smith Rjh (ORCID: https://orcid.org/0000-0003-1907-3392)
- Andrea S. Henden (ORCID: https://orcid.org/0000-0003-2261-169X)
- Katie E. Lineburg (ORCID: https://orcid.org/0000-0002-5712-2610)
- K. Guppy-Coles (ORCID: https://orcid.org/0000-0002-2928-2983)
- Justine Leach
- Jyothy Raju
- Siok-Keen Tey
- Louise Ng
- Annabel Waugh
- Sophie C. Hamann
- Laetitia Le Texier
- Christine Bristow
Institutions
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Royal Brisbane and Women's Hospital (AU)
Publication Details
- Journal
- Vaccines
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3390/vaccines14030201
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- QIMR Berghofer Medical Research Institute
- Australian Government
- Metro North Hospital and Health Service